🏢 官网IRCTNMQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 04:05:00(美东 08-25 16:05)·⟳ 抓取 04:07:50·⚡ 决策 08-26 04:09:54 +2m04s·62.9 天前
Contineum Therapeutics宣布将于9月15日在Morgan Stanley全球医疗健康大会进行炉边对话
这是一条纯粹的例行IR活动公告——公司宣布三周后将参加一场投行会议的炉边对话。没有新临床数据、没有业绩指引变化、没有合作/订单/监管进展，事件方向为中性，不存在任何可交易的增量信息或方向性edge。Web/KB/行情研究均不可能改变此结论。
📄 原文CTNM↗ 原文
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET . An audio webcast of the firesi…
不做 Contineum Therapeutics（CTNM.US）
例行会议出席公告（9月15日Morgan Stanley Global Healthcare Conference fireside chat），无任何新临床数据、业绩指引、合作或监管信息，事件方向中性，不构成可交易催化，无edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Contineum Therapeutics (CTNM.US) 于2026-08-25盘后发布公告，宣布将于9月15日参加Morgan Stanley Global Healthcare Conference并进行炉边对话。这是标准的投资者关系活动通知，不包含任何新临床数据、业绩指引、合作、订单或监管信息。事件方向中性，无增量事实，不构成交易催化。
🔎 新鲜度:最早出现 2026-08-25 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:先例研究不适用于此类无增量信息的例行IR公告
方向:无先例可参考——例行会议出席公告历史上不产生可测量的股价反应
涨幅量级:不适用
形态:不适用
工具调用 · 历史记录,结果未知(1 种)
- search_processed_events · 结果未知
原文全文
展开原文 · 1,141 字
Morgan Stanley Global Healthcare Conference
on
Tuesday, September 15th
at
5:35 p.m. ET
.
An audio webcast of the fireside chat can be accessed on the
Investors
section of Contineum’s website. A webcast replay will also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit
www.contineum-tx.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260825617969/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
on
Tuesday, September 15th
at
5:35 p.m. ET
.
An audio webcast of the fireside chat can be accessed on the
Investors
section of Contineum’s website. A webcast replay will also be available.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder. For more information, please visit
www.contineum-tx.com
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20260825617969/en/
Steve Kunszabo
Contineum Therapeutics
Senior Director, Investor Relations & Corporate Communications
858-649-1158
skunszabo@contineum-tx.com
Source: Contineum Therapeutics, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。